Search
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Ephedra sinica root
go.drugbank.com/drugs/DB01363ApprovedNutraceuticalThe drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma. … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for
Products: Fyto-HB I- Cap 10mgRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalDelayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Eucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalIt kills leukaemia cells in vitro. … Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant.
Mixtures: Demo Cineol InjCategories: Compounds used in a research, industrial, or household settingCupric oxide
go.drugbank.com/drugs/DB11134ApprovedCopper(II) oxide nanoparticles (NPCuO) have industrial applications as antimicrobial agents in textiles and paints, and catalysts in organic synthesis [A32656]. … Cupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics.
Mixtures: Virt-Pn, Virt-PNMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Sodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnSodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. … As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational; Both biosimilars also received marketing authorization in the EU in May 2024. … for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].